Susan Dorman, MD

Faculty

Titles:

Associate Professor, Medicine

SciVal:

SciVal Link

Dr. Dorman and her research team at JHU focus on the development and assessment of new tuberculosis diagnostic tests and strategies and new tuberculosis treatment strategies.  Her team’s multidisciplinary work in tuberculosis diagnostics includes test development, accuracy assessments, implementation research, economic evaluations, and mathematical modeling.  Dr. Dorman serves as co-Principal investigator with Dr. Jerrold Ellner on a U.S. National Institutes of Health-funded contract, the ‘Tuberculosis Clinical Diagnostics Research Consortium’, whose mission is to conduct early stage assessments of novel diagnostic tests for tuberculosis at study sites in China, South Korea, South Africa, Kenya, Uganda, and Brazil.  She also serves as Principal Investigator on phase I, II, and III clinical trials of rifapentine, including multicenter international trials of the CDC Tuberculosis Trials Consortium. 

Categories

Events

«

March 2019

»
S
M
T
W
T
F
S
·
·
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
·
·
·
·
·
·

Projects

mHealth for improved TB contact investigation...

This multicenter randomized study is evaluating the implementation, effectiveness, cost-effectiveness, and population-level...

Read More

A randomized trial of preventive therapy for...

We are evaluating the efficacy and cost-effectiveness of levofloxacin preventive therapy for adult contacts of MDR TB patients...

Read More

Understanding the costs and...

We have conducted an empirical costing analysis of facility-based versus community-based treatment for TB in Bangladesh and are...

Read More

Evaluation of a novel serum biosignature for...

This study will use multiple high-throughput modalities, including LC-MS/MS and RNA-seq, to detect a panel of host metabolites...

Read More

Scale-up and implementation of TB diagnostics...

We are evaluating the implementation, cost-effectiveness, and potential epidemiological impact of scaling up Xpert across 19...

Read More